Screening 1: *Pregnant women with:*
- HIV-1 infection post-VCT
- not eligible for HAART
- intention to breastfeed
- CD4 as per national guideline (min. 350 cells/µL)
- Intention to participate
- Antenatal screening consent

Infant feeding counselling

Antenatal clinics, from week 28 of gestation

Study site, Counselling

Infant feeding counselling

Maternity

Delivery with routine national PMTCT

Study site, Day 1-6

Screening 2: *Newborn:*
- HIV-1 DNA PCR
- Biochemistry
- Clinical examination

*Mother:*
- Screening 2 consent

Newborn/Mother: Inclusion/exclusion criteria

Study site, Day 1-6

Not included: Regular postnatal care or paediatric referral if required

Enrolment and Randomisation

Study site, Follow-up visit

Infant:
- HIV-1 infection (PCR) at prior visits and / or
- Adverse events

Follow-up:

Infected or severe adverse events: Withdrawn from study medication but followed for outcomes

Completion of follow-up

Study site, Follow-up visit